Karuna Therapeutics Inc expected to post a loss of $2.74 a share - Earnings Preview

Karuna Therapeutics

31/10/2023 17:46

* Karuna Therapeutics Inc  KRTX.OQ   KRTX.O  is expected
to show a
rise in quarterly revenue when it reports  results 
    * The Boston Massachusetts-based  company is expected to
report  a
1,449.4% increase in revenue to $1.255 million from $81 thousand
a year ago, according to the mean estimate from 16 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Karuna Therapeutics
Inc
is for a loss of $2.74 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 18 "strong buy" or "buy," 2
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Karuna
Therapeutics Inc is $270​, above​ its last closing price
of $161.90. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2023  -2.80       -2.78      -2.75     Beat    0.9
 Mar. 31 2023  -2.79       -2.76      -2.80     Missed  -1.6
 Dec. 31 2022  -2.37       -2.25      -2.22     Beat    1.2​
 Sep. 30 2022  -2.13       -2.13      -2.38     Missed  -11.5
 ​​Jun.        -2.04       -2.09      -2.17     Missed  -3.6
 30 2022                                                
 Mar. 31 2022  -2.18       -2.11      -1.95     Beat    7.6​
 Dec. 31 2021  -1.66       -1.73      -0.94     Beat    45.8
 Sep. 30 2021  -1.45       -1.44      -1.72     Missed  -19.4
 This summary was machine generated October 31 at 17:46 GMT.  All
figures in US dollars  unless otherwise stated